Key clinical point: A new self-expanding transcatheter aortic valve replacement prosthesis did not meet noninferiority, compared with the SAPIEN 3.
Major finding: The primary endpoint rate in the intention-to-treat cohort for ACURATE neo was 23.7%, compared with 16.5% with SAPIEN 3 (P for noninferiority = 0.42).
Study details: A randomized, comparative trial of 739 patients with severe, symptomatic aortic stenosis at increased surgical risk.
Disclosures: SCOPE I was an investigator-initiated and -conducted study funded by a dedicated research grant from Symetis in Ecublens, Switzerland (part of Boston Scientific). Dr. Lanz had nothing to disclose.